Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. - Giovannetti E; Labots M; Dekker H; Galvani E; Lind JS; Sciarrillo R; Honeywell R; Smit EF; Verheul HM; Peters GJ (Current pharmaceutical design, 2013)